YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Generic Utilization in the Korean National Health Insurance Market; Cost, Volume and Influencing Factors

한국 국민건강보험시장에서의 제네릭 의약품 사용 양상과 영향 요인

  • Received : 2013.11.27
  • Accepted : 2014.04.02
  • Published : 2014.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study explores the prescribing pattern of generic drugs and the relationship between socio-demographic factors and the use of generics in South Korea. The analysis was based on claims data of 2011 from Korean National Health Insurance. We examined utilization, costs, and market share of oral preparations by original and generic product. Multiple logistic regression was performed to evaluate the predictive factors of generic use among multi-source medications. Generics accounted for 37~41% of utilization and 34~41% of costs in the insured market of oral preparations. In the generic market, costly generics made up about 58~61%, 56~66% of volume and value, respectively. Other things being equal, institutional factors affected generic use to the largest degree. The odds of having generics were 6 times higher in clinics, 4 times higher in hospitals, and 1.7 times higher in general hospitals than in teaching hospitals. Those in metropolitan or rural area were more likely to prescribe generics than those in the capital area. While generics were frequently prescribed for off-site pharmacy (OR=1.173), the odds of having generics was 0.88 after weighting the data by units prescribed. This study empirically presented the pattern of generic prescribing, confirming the widely accepted view that costly generics were more likely to be utilized in the Korean market. Up to two thirds of the generic market consisted of costly products. The strongest factors affecting generic use were institutional variables.

Keywords

References

  1. Jacobzone, S. : Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Paris, Organisation for Economic Co-operation and Development (2000).
  2. National Economic Research Associates: Policy relating to generic medicines in the OECD. London, European Commission, National Economic Research Associates (1998).
  3. Simoens, S. and De Coster, S. : Sustaining generic medicines markets in Europe. Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven (2006).
  4. Vogler, S., Zimmermann, N., Leopold, C. and de Joncheere, K. : Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev. 4, 69 (2011).
  5. Rhee, J. and Shin, G. : Factors associated with fixed budgets for pharmaceuticals in European Countries. Yakhak Hoeji 57, 213 (2013).
  6. OECD : Health at a glance 2011: OECD indicators. OECD Publishing (2011).
  7. Jang, S., Park, C.-M., Bae, G., Lee, H.-J. and Kim, H.-S. : Determinants of publicly funded drug expenditure in South Korea. Seoul, Health Insurance Review & Assessment Service (2011).
  8. Kim, S.-O. : Realities in expensive drug prescribing and its determinants. Health Insurance Forum. 4, 57 (2005).
  9. Yoon, H.-S. : National Insurance reimbursement pricing scheme: challenges and a strategy for improvement. Seoul, Korea Development Institute (2008).
  10. Lee, T.-L., Hsuan, C.-F., Chang, H.-L., Wu, G. H.-M., Tseng, W.-K. and Wu, C.-C. : Is it cost-effective to change brand-name to generic simvastatin in Taiwan? Acta Cardiologica Sinica. 24, 191 (2008).
  11. Kanavos, P. : Do generics offer significant savings to the UK National Health Service? Current Medical Research & Opinion. 23, 105 (2007). https://doi.org/10.1185/030079907X159506
  12. Chen, A. Y. and Wu, S. : Dispensing pattern of generic and brand-name drugs in children. Ambulatory Pediatrics. 8, 189 (2008). https://doi.org/10.1016/j.ambp.2007.12.008
  13. Fischer, M. A. and Avorn, J. : Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Services Research 38, 1051 (2003). https://doi.org/10.1111/1475-6773.00162
  14. Morgan, S. G., Bassett, K. L., Wright, J. M., Evans, R. G., Barer, M. L., Caetano, P. A. and Black, C. D. : "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ 331, 815 (2005). https://doi.org/10.1136/bmj.38582.703866.AE
  15. Huh, S.-I., Jung, J.-C. and Lee, H.-Y. : A strategy for rationalising pharmaceutical expenditure. Seoul, National Health Insurance Corporation (2006).
  16. You, M.-Y. : A study on the market-share of original drugs since first generic entry. Graduate School of Public Health. Seoul, Yonsei University (2007).
  17. Shin, J.-Y. and Choi, S.-E. : The volume and the price of generic drug consumption in Korean prescription drug market. The Korean Journal of Health Economics and Policy. 14, 103 (2008).
  18. Lee, I.-H. : Evaluating pharmaceutical policy in South Korea. Health Sciences. York, University of York (2010).
  19. Park, S., Jang, Y.-S., Chae, S.-M., Park, E.-J., Kim, N.-S., Lee, E. K. and Lee, I.-H. : An indepth study of the utilization and costs of pharmaceuticals in South Korea, 2010]. Seoul, Ministry of Health & Welfare, Korea Institute for Health and Social Affairs (2011).
  20. Park, S., Jang, Y.-S., Chae, S.-M., Park, E.-J., Lee, E. K. and Lee, I.-H. : An indepth study of the utilization and costs of pharmaceuticals in South Korea, 2011. Seoul, Ministry of Health & Welfare, Korea Institute for Health and Social Affairs (2012).
  21. Bulfone, L. : High prices for generics in Australia- more competition might help. Australian Health Review 33, 200 (2009). https://doi.org/10.1071/AH090200
  22. Schweitzer, S. O. : The worldwide market for pharmaceuticals. Pharmaceutical economics and policy. 2nd ed. Oxford University Press. New York. p. 157 (2007).
  23. Vogel, R. J. : Sales and marketing expenditures. Pharmaceutical economics and public policy. Pharmaceutical Products Press. New York. p. 147 (2007).
  24. Cassels, A. and Lexchin, J. : Potential savings from therapeutic substitution of 10 of Canada's most dispensed prescription drugs. In: Temple NJ, Thompson A, eds. Radcliffe Publishing Ltd. Norfolk. p. 80 (2007).
  25. Health Insurance Review & Assessment Service: Comprehensive quality report of National Health Insurance 2009. Seoul, Health Insurance Review & Assessment Service (2010).